Bio-Rad Laboratories, Inc. Class A Common Stock vs ProShares UltraPro Short QQQ ETF — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $358.05 (market cap $9.43B), while ProShares UltraPro Short QQQ ETF trades at $37.09. The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals.
| BIO | SQQQ | |
|---|---|---|
Market Cap | $9.43B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $356.25 | $92.95 |
52-Week Low | $241.71 | $36.31 |
Enterprise Value | $9.18B | — |
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $351.10, down 0.97% on the day but maintaining strength near its 52-week high. The stock shows bullish technical momentum with strong moving average support and recently beat Q2 2026 earnings estimates with $2.62 EPS versus $1.75 expected. Fundamentals show improving profitability with 29.41% net margin in 2025, though revenue remains flat at $2.6 billion. Analyst consensus remains positive with 7 buy ratings and $350 price target.
BIO presents a mixed outlook with strong technical momentum and improving profitability offset by flat revenue growth and elevated valuation multiples. The stock's current price aligns with analyst consensus target, suggesting limited near-term upside. Key risks include academic research market softness and competitive pressures in life science instruments. Institutional ownership trends show continued confidence with recent position increases by major funds.
SQQQ, a 3x leveraged inverse ETF tracking the Nasdaq-100, trades at $37.15, down 1.56% on the day. Technical indicators are bearish overall, with moving averages signaling selling pressure, though oscillators are neutral. The ETF is designed for short-term tactical use, not long-term holding, due to daily resets that erode value over time.
The outlook for SQQQ is highly speculative, offering potential gains if the Nasdaq-100 declines, but risks are severe, including rapid decay from leverage and volatility decay. It may serve as a hedge for QQQ holdings but is unsuitable as a standalone investment given its long-term performance history of significant losses.
Trailing returns across standard periods
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →